NCT01277744 · OUTCOME

Recurrence Free Survival

Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor · Source last updated 2020-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 36 months after the last participant enrolled

What was measured

Date of surgery to date of death or date of recurrence, whichever occurred first for patients who experienced an event, and to date of last follow-up for patients alive without recurrence

Groups in this outcome

HIPEC

HIPEC with Cisplatin

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
HIPEC	20

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
HIPEC	13.99	Not reported	7.26	NA	95 percent are upper limit was not estimable

Complete source fields

classes

categories
measurements
comment
95 percent are upper limit was not estimable
group Id
OG000
lower Limit
7.26
upper Limit
NA
value
13.99

denoms

counts
group Id
OG000
value
20
units
Participants

description

Date of surgery to date of death or date of recurrence, whichever occurred first for patients who experienced an event, and to date of last follow-up for patients alive without recurrence

dispersion Type

95% Confidence Interval

groups

description
HIPEC with Cisplatin
id
OG000
title
HIPEC

param Type

MEDIAN

reporting Status

POSTED

time Frame

36 months after the last participant enrolled

title

Recurrence Free Survival

type

PRIMARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice